We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




MRI Reveals Early Impact of Hypertension on Dementia Risk

By HospiMedica International staff writers
Posted on 11 Jul 2018
A new study shows how magnetic resonance imaging (MRI) can reveal previously undetectable white matter (WM) brain damage induced by hypertension, a major risk factor for dementia.

Researchers at IRCCS Neuromed (Pozzilli, Italy) and Sapienza University (Rome, Italy; www.uniroma1.it) conducted a study involving 42 outpatients (40-65 years of age), of whom 23 were hypertensive and 19 normotensive. More...
The researchers first measured the cognitive performance of study participants with no signs of dementia or structural brain changes (as determined by a neuroradiologist), based on conventional MRI on T1 and AX DP/T2 scans. They then repeated imaging using WM fiber-tracking technology on a GE Healthcare (GE; Little Chalfont, United Kingdom; www.gehealthcare.com) 3T Signa Horizon scanner.

In addition, a blinded, certified psychologist tested cognitive function and looked for any impairment of activities of daily living at baseline. Participants then underwent Montreal Cognitive Assessment (MoCA) neuropsychological testing. When specific MoCA cognitive subdomains were analyzed, the hypertensive group displayed significantly impaired memory, executive function, attention, and language domains, and scored worse on verbal paired-associate learning. Hypertension also appeared to impair executive function, as measured on the Stroop test.

When comparing WM finding between those with and without hypertension, specific signatures for dementia risk among hypertensive patients involved deterioration of projection fibers of the right anterior thalamic radiation (ATR), association fibers of the right superior longitudinal fasciculus (SLF), and callosum fibers of the forceps minor (FMI). The researchers concluded that WM tracking could identify patients in initial stages of brain damage that could benefit from therapies aimed at limiting the transition to dementia and neurodegeneration. The study was published on June 12, 2018, in Cardiovascular Research.

“All hypertensive participants were taking antihypertensive therapy, suggesting that an efficient anti-hypertensive therapy is not sufficient to exclude the onset of vascular dementia or protect the brain from white matter microstructural damage,” said lead author graduate student Lorenzo Carnevale, MSc, of NeuroMed. “Our results point out a big issue in current cardiovascular diseases treatment: We can't ignore the brain. Current therapies are not tailored to ensure at the same time cardiovascular protection and cognitive function protection.”

The ATR is a projection fiber that connects the thalamus's anterior nucleus to the anterior cingulate gyrus and frontal cortex, and ATR damage is associated with impaired memory. The SLF connects the cerebrum parietal and occipital and temporal lobes with the ipsilateral frontal cortices; it facilitates the formation of a bidirectional neural network necessary for cognitive functions, such as attention, memory, emotions, and language. The FMI connects the frontal lobes' lateral and medial surfaces, crosses the midline via the genu of the corpus callosum, and has been linked to processing speed tasks.

Related Links:
IRCCS Neuromed


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
Blood Gas Analyzer
i-Check200
Gas Analyzer
GE SAM
Vessel Sealing Instrument
ERGOseal
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image Credit: Adobe Stock

AI Platform Personalizes Support Between Visits for Cancer Survivors

Cancer survivors often manage persistent side effects after treatment, including fatigue, anxiety, uncertainty, symptoms, stress, and questions between appointments. Clinical teams need ways to maintain... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: The proposed acquisition would add NeoCast, an investigational next-generation liquid embolic technology for chronic subdural hematoma (cSDH), to Terumo Neuro’s neurovascular portfolio. (Photo courtesy of Arsenal Medical)

Terumo Neuro Acquisition Advances Liquid Embolic Technology for Chronic Subdural Hematoma

Terumo Neuro (Aliso Viejo, CA, USA) signed an agreement to acquire Arsenal Medical Inc. (Waltham, MA, USA), a privately held, clinical-stage biomaterials company. The proposed acquisition would add NeoCast,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.